An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI).
Phase of Trial: Phase IV
Latest Information Update: 09 Oct 2012
At a glance
- Drugs Esomeprazole; Proton pump inhibitors
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Acronyms NEON
- Sponsors AstraZeneca
- 04 Nov 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
- 05 Sep 2008 New trial record.